Literature DB >> 30365092

COX-2 induces apoptosis-resistance in hepatocellular carcinoma cells via the HIF-1α/PKM2 pathway.

Qin Wang1, Donghui Lu1, Lulu Fan1, Yuhuan Li1, Yu Liu1, Hanqing Yu1, Hua Wang1, Jiatao Liu1, Guoping Sun1.   

Abstract

The pyruvate kinase M2 isoform (PKM2) is a key component of aerobic glycolysis and has been reported to regulate apoptosis. However, it is unclear whether PKM2 is involved in cyclooxygenase‑2 (COX‑2) induced apoptosis‑resistance in hepatocellular carcinoma (HCC) cells. In the present study, it was observed that COX‑2 and PKM2 were significantly elevated in hepatocellular carcinoma tissues compared with adjacent liver tissues (P<0.05). Furthermore, their expression was positively associated with worse clinicopathological characteristics, which indicates poor prognosis in patients with HCC. COX‑2 knockdown significantly reduced the expression of PKM2 and hypoxia inducible factor‑1α (HIF‑1α) at the mRNA and protein levels in addition to inhibiting proliferation (P<0.05), whereas apoptosis was notably increased. Furthermore, HIF‑1α and PKM2‑knockdown increased cell apoptosis without inhibiting COX‑2 expression. PKM2 inhibition did not have a marked effect on COX‑2 and HIF‑1α expression. In conclusion, the results of the present study suggested that HIF‑1α/PKM2 pathway‑associated metabolic changes may facilitate COX‑2‑induced apoptosis resistance in HCC cells.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30365092     DOI: 10.3892/ijmm.2018.3936

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  4 in total

Review 1.  The Role of PKM2 in the Regulation of Mitochondrial Function: Focus on Mitochondrial Metabolism, Oxidative Stress, Dynamic, and Apoptosis. PKM2 in Mitochondrial Function.

Authors:  Jing Gao; Yuwei Zhao; Tao Li; Xueqi Gan; Haiyang Yu
Journal:  Oxid Med Cell Longev       Date:  2022-05-06       Impact factor: 7.310

Review 2.  Targeting the eicosanoid pathway in hepatocellular carcinoma.

Authors:  Anshuli Razdan; Nathan M Main; Vincent Chiu; Nicholas A Shackel; Paul de Souza; Katherine Bryant; Kieran F Scott
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

3.  LNCAROD enhances hepatocellular carcinoma malignancy by activating glycolysis through induction of pyruvate kinase isoform PKM2.

Authors:  Guizhi Jia; Yan Wang; Chengjie Lin; Shihui Lai; Hongliang Dai; Zhiqian Wang; Luo Dai; Huizhao Su; Yanjie Song; Naiwen Zhang; Yukuan Feng; Bo Tang
Journal:  J Exp Clin Cancer Res       Date:  2021-09-22

4.  Targeting of the COX-2/PGE2 axis enhances the antitumor activity of T7 peptide in vitro and in vivo.

Authors:  Jianrong Yang; Jingtao Zhong; Mi Zhou; Yinghong Zhou; Peng Xiu; Feng Liu; Fuhai Wang; Zelun Li; Yuntian Tang; Yuanyuan Chen; Siyang Yao; Tao Huang; Tianqi Liu; Xiaofeng Dong
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.